{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T18:50:05Z","timestamp":1778784605642,"version":"3.51.4"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2019,5,22]],"date-time":"2019-05-22T00:00:00Z","timestamp":1558483200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2019,5,22]],"date-time":"2019-05-22T00:00:00Z","timestamp":1558483200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100002973","name":"Daiichi-Sankyo","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002973","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2019,7]]},"DOI":"10.1007\/s12325-019-00956-z","type":"journal-article","created":{"date-parts":[[2019,5,23]],"date-time":"2019-05-23T05:17:07Z","timestamp":1558588627000},"page":"1618-1627","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Absolute Bioavailability of Esaxerenone and Food Effects on its Pharmacokinetics After a Single Oral Dose in Healthy Japanese Subjects: An Open-Label Crossover Study"],"prefix":"10.1007","volume":"36","author":[{"given":"Akifumi","family":"Kurata","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hidetoshi","family":"Furuie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomoko","family":"Ishizuka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takafumi","family":"Nakatsu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takako","family":"Shimizu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manabu","family":"Kato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuhiro","family":"Nishikawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hitoshi","family":"Ishizuka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,5,22]]},"reference":[{"key":"956_CR1","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1038\/hr.2013.80","volume":"37","author":"K Shimamoto","year":"2014","unstructured":"Shimamoto K, Ando K, Fujita T, et al. The Japanese Society of hypertension guidelines for the management of hypertension (JSH 2014). Hypertens Res. 2014;37:253\u2013390. \n                    https:\/\/doi.org\/10.1038\/hr.2014.20\n                    \n                  .","journal-title":"Hypertens Res"},{"key":"956_CR2","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1161\/01.HYP.0000107251.49515.c2","volume":"42","author":"AV Chobanian","year":"2003","unstructured":"Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure. Hypertension. 2003;42:1206\u201352. \n                    https:\/\/doi.org\/10.1161\/01.HYP.0000107251.49515.c2\n                    \n                  .","journal-title":"Hypertension"},{"key":"956_CR3","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1111\/j.1524-6175.2006.05504.x","volume":"8","author":"MA Tedesco","year":"2006","unstructured":"Tedesco MA, Natale F, Calabro R. Effects of monotherapy and combination therapy on blood pressure control and target organ damage: a randomized prospective intervention study in a large population of hypertensive patients. J Clin Hypertens (Greenwich). 2006;8:634\u201341.","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"956_CR4","doi-asserted-by":"publisher","first-page":"2159","DOI":"10.1093\/eurheartj\/eht151","volume":"34","author":"G Mancia","year":"2013","unstructured":"Mancia G, Fagard R, Narkiewicz K, et al. 2013 ESH\/ESC guidelines for the management of arterial hypertension. Eur Heart J. 2013;34:2159\u2013219.","journal-title":"Eur Heart J"},{"key":"956_CR5","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.1093\/ajh\/hpv031","volume":"28","author":"K Dahal","year":"2015","unstructured":"Dahal K, Kunwar S, Rijal J, et al. The effects of aldosterone antagonists in patients with resistant hypertension: a meta-analysis of randomized and nonrandomized studies. Am J Hypertens. 2015;28:1376\u201385. \n                    https:\/\/doi.org\/10.1093\/ajh\/hpv031\n                    \n                  .","journal-title":"Am J Hypertens"},{"key":"956_CR6","doi-asserted-by":"publisher","first-page":"2059","DOI":"10.1016\/S0140-6736(15)00257-3","volume":"386","author":"B Williams","year":"2015","unstructured":"Williams B, MacDonald TM, Morant S, et al. Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial. Lancet. 2015;386:2059\u201368. \n                    https:\/\/doi.org\/10.1016\/S0140-6736(15)00257-3\n                    \n                  .","journal-title":"Lancet"},{"key":"956_CR7","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1038\/ajh.2011.245","volume":"25","author":"H Shibata","year":"2012","unstructured":"Shibata H, Itoh H. Mineralocorticoid receptor-associated hypertension and its organ damage: clinical relevance for resistant hypertension. Am J Hypertens. 2012;25:514\u201323. \n                    https:\/\/doi.org\/10.1038\/ajh.2011.245\n                    \n                  .","journal-title":"Am J Hypertens"},{"key":"956_CR8","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1016\/j.amjmed.2016.01.039","volume":"129","author":"M Epstein","year":"2016","unstructured":"Epstein M, Duprez DA. Resistant hypertension and the pivotal role for mineralocorticoid receptor antagonists: a clinical update 2016. Am J Med. 2016;129:661\u20136. \n                    https:\/\/doi.org\/10.1016\/j.amjmed.2016.01.039\n                    \n                  .","journal-title":"Am J Med"},{"key":"956_CR9","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1038\/jhh.2015.119","volume":"30","author":"S Takahashi","year":"2016","unstructured":"Takahashi S, Katada J, Daida H, Kitamura F, Yokoyama K. Effects of mineralocorticoid receptor antagonists in patients with hypertension and diabetes mellitus: a systematic review and meta-analysis. J Hum Hypertens. 2016;30:534\u201342. \n                    https:\/\/doi.org\/10.1038\/jhh.2015.119\n                    \n                  .","journal-title":"J Hum Hypertens"},{"key":"956_CR10","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1007\/s11906-016-0643-8","volume":"18","author":"H Narayan","year":"2016","unstructured":"Narayan H, Webb DJ. New evidence supporting the use of mineralocorticoid receptor blockers in drug-resistant hypertension. Curr Hypertens Rep. 2016;18:34. \n                    https:\/\/doi.org\/10.1007\/s11906-016-0643-8\n                    \n                  .","journal-title":"Curr Hypertens Rep"},{"key":"956_CR11","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/j.ejphar.2015.11.028","volume":"769","author":"K Arai","year":"2015","unstructured":"Arai K, Tsuruoka H, Homma T. CS-3150, a novel non-steroidal mineralocorticoid receptor antagonist, prevents hypertension and cardiorenal injury in Dahl salt-sensitive hypertensive rats. Eur J Pharmacol. 2015;769:266\u201373. \n                    https:\/\/doi.org\/10.1016\/j.ejphar.2015.11.028\n                    \n                  .","journal-title":"Eur J Pharmacol"},{"key":"956_CR12","doi-asserted-by":"publisher","first-page":"e173","DOI":"10.1097\/01.hjh.0000523471.25362.f5","volume":"35","author":"S Ito","year":"2017","unstructured":"Ito S, Itoh H, Rakugi H, Okuda Y, Yamakawa S. Treatment with esaxerenone (CS-3150) is associated with a significant dose-dependent antihypertensive effect in essential hypertensive patients. J Hypertens. 2017;35:e173. \n                    https:\/\/doi.org\/10.1097\/01.hjh.0000523471.25362.f5\n                    \n                  .","journal-title":"J Hypertens"},{"key":"956_CR13","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1080\/00498254.2016.1263766","volume":"47","author":"M Yamada","year":"2017","unstructured":"Yamada M, Takei M, Suzuki E, et al. Pharmacokinetics, distribution, and disposition of esaxerenone, a novel, highly potent and selective non-steroidal mineralocorticoid receptor antagonist, in rats and monkeys. Xenobiotica. 2017;47:1090\u2013103. \n                    https:\/\/doi.org\/10.1080\/00498254.2016.1263766\n                    \n                  .","journal-title":"Xenobiotica"},{"key":"956_CR14","doi-asserted-by":"publisher","first-page":"1821","DOI":"10.1111\/bcp.13616","volume":"84","author":"M Kato","year":"2018","unstructured":"Kato M, Furuie H, Shimizu T, Miyazaki A, Kobayashi F, Ishizuka H. Single- and multiple-dose escalation study to assess pharmacokinetics, pharmacodynamics and safety of oral esaxerenone in healthy Japanese subjects. Br J Clin Pharmacol. 2018;84:1821\u20139. \n                    https:\/\/doi.org\/10.1111\/bcp.13616\n                    \n                  .","journal-title":"Br J Clin Pharmacol"},{"key":"956_CR15","unstructured":"US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER). 2002. Guidance for industry food effect bioavailability and fed bioequivalence studies. \n                    https:\/\/www.fda.gov\/downloads\/drugs\/guidancecomplianceregulatoryinformation\/guidances\/ucm070241.pdf\n                    \n                  . Accessed 18 Feb 2019."},{"key":"956_CR16","doi-asserted-by":"publisher","DOI":"10.1201\/9781420036091","volume-title":"Design and analysis of cross-over trials","author":"B Jones","year":"2003","unstructured":"Jones B, Kenward MG. Design and analysis of cross-over trials. 2nd ed. London: Chapman & Hall; 2003.","edition":"2"},{"key":"956_CR17","doi-asserted-by":"publisher","first-page":"233","DOI":"10.2165\/00003088-199936030-00004","volume":"36","author":"D Fleisher","year":"1999","unstructured":"Fleisher D, Li C, Zhou Y, Pao LH, Karim A. Drug, meal and formulation interactions influencing drug absorption after oral administration. Clinical implications. Clin Pharmacokinet. 1999;36:233\u201354. \n                    https:\/\/doi.org\/10.2165\/00003088-199936030-00004\n                    \n                  .","journal-title":"Clin Pharmacokinet"},{"key":"956_CR18","unstructured":"US Department of Health and Human Services. Food and Drug Administration. Center for Drug Evaluation and Research (CDER). 2017. Biopharmaceutics. Waiver of in vivo bioavailability and bioequivalence studies for immediate-release solid oral dosage forms based on a biopharmaceutics classification system. Guidance for industry. \n                    https:\/\/www.fda.gov\/downloads\/Drugs\/Guidances\/ucm070246.pdf\n                    \n                  . Accessed 14 Sept 2018."},{"key":"956_CR19","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1124\/dmd.118.084897","volume":"47","author":"M Yamada","year":"2018","unstructured":"Yamada M, Mendell H, Takakusa H, Shimizu T, Ando O. Pharmacokinetics, metabolism, and excretion of [14C]esaxerenone, a novel mineralocorticoid receptor blocker in humans. Drug Metab Dispos. 2018;47:340\u20139. \n                    https:\/\/doi.org\/10.1124\/dmd.118.084897\n                    \n                  .","journal-title":"Drug Metab Dispos"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-019-00956-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12325-019-00956-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-019-00956-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,20]],"date-time":"2020-05-20T23:13:33Z","timestamp":1590016413000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12325-019-00956-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,22]]},"references-count":19,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2019,7]]}},"alternative-id":["956"],"URL":"https:\/\/doi.org\/10.1007\/s12325-019-00956-z","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,5,22]]},"assertion":[{"value":"26 February 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 May 2019","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}